154 related articles for article (PubMed ID: 36621759)
1. Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia.
Assayag D; Adegunsoye A; Sheehy R; Morisset J; Khalil N; Johannson KA; Marcoux V; Kolb M; Fisher JH; Manganas H; Wrobel J; Wilsher M; De Boer S; Mackintosh J; Chambers DC; Glaspole I; Keir GJ; Lee CT; Jablonski R; Vij R; Strek ME; Corte TJ; Ryerson CJ
Chest; 2023 May; 163(5):1156-1165. PubMed ID: 36621759
[TBL] [Abstract][Full Text] [Related]
2. Treatment Initiation in Patients with Interstitial Lung Disease in Canada.
Assayag D; Garlick K; Johannson KA; Fell CD; Kolb M; Cox G; Hambly N; Manganas H; Morisset J; Fisher JH; Shapera S; Gershon AS; To T; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Ryerson CJ
Ann Am Thorac Soc; 2021 Oct; 18(10):1661-1668. PubMed ID: 33493425
[No Abstract] [Full Text] [Related]
3. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.
Fisher JH; Kolb M; Algamdi M; Morisset J; Johannson KA; Shapera S; Wilcox P; To T; Sadatsafavi M; Manganas H; Khalil N; Hambly N; Halayko AJ; Gershon AS; Fell CD; Cox G; Ryerson CJ
BMC Pulm Med; 2019 Nov; 19(1):223. PubMed ID: 31771541
[TBL] [Abstract][Full Text] [Related]
4. Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease.
Khor YH; Goh NSL; Wong AW; Johannson KA; Marcoux V; Fisher JH; Assayag D; Manganas H; Khalil N; Kolb M; Ryerson CJ;
Ann Am Thorac Soc; 2022 Jun; 19(6):962-970. PubMed ID: 35007498
[No Abstract] [Full Text] [Related]
5. Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database.
Moore I; Wrobel J; Rhodes J; Lin Q; Webster S; Jo H; Troy L; Grainge C; Glaspole I; Corte TJ;
BMC Pulm Med; 2020 Oct; 20(1):257. PubMed ID: 33008362
[TBL] [Abstract][Full Text] [Related]
6. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
Wong AW; Lee TY; Johannson KA; Assayag D; Morisset J; Fell CD; Fisher JH; Shapera S; Gershon AS; Cox G; Halayko AJ; Hambly N; Manganas H; Sadatsafavi M; Wilcox PG; To T; Marcoux V; Khalil N; Kolb M; Ryerson CJ
Respir Res; 2020 Dec; 21(1):322. PubMed ID: 33287805
[TBL] [Abstract][Full Text] [Related]
7. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
Hyldgaard C
Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
[TBL] [Abstract][Full Text] [Related]
8. Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis.
Lee CT; Strek ME; Adegunsoye A; Wong AW; Assayag D; Cox G; Fell CD; Fisher JH; Gershon AS; Halayko AJ; Hambly N; Khalil N; Kolb M; Lok SD; Manganas H; Marcoux V; Morisset J; Sadatsafavi M; Shapera S; To T; Wilcox P; Ryerson CJ; Johannson KA
Respirology; 2022 Aug; 27(8):635-644. PubMed ID: 35512793
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
[TBL] [Abstract][Full Text] [Related]
13. Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients With Interstitial Lung Disease.
Cutting CC; Bowman WS; Dao N; Pugashetti JV; Garcia CK; Oldham JM; Newton CA
Chest; 2021 May; 159(5):1913-1921. PubMed ID: 33484728
[TBL] [Abstract][Full Text] [Related]
14. Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry.
Buschulte K; Kabitz HJ; Hagmeyer L; Hammerl P; Esselmann A; Wiederhold C; Skowasch D; Stolpe C; Joest M; Veitshans S; Höffgen M; Maqhuzu P; Schwarzkopf L; Hellmann A; Pfeifer M; Behr J; Karpavicius R; Günther A; Polke M; Höger P; Somogyi V; Lederer C; Markart P; Kreuter M
Respir Res; 2024 Mar; 25(1):113. PubMed ID: 38448953
[TBL] [Abstract][Full Text] [Related]
15. Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry.
Buschulte K; Kabitz HJ; Hagmeyer L; Hammerl P; Esselmann A; Wiederhold C; Skowasch D; Stolpe C; Joest M; Veitshans S; Höffgen M; Maqhuzu P; Schwarzkopf L; Hellmann A; Pfeifer M; Behr J; Karpavicius R; Günther A; Polke M; Höger P; Somogyi V; Lederer C; Markart P; Kreuter M
Respir Res; 2024 Jan; 25(1):5. PubMed ID: 38178212
[TBL] [Abstract][Full Text] [Related]
16. Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease.
Algamdi M; Sadatsafavi M; Fisher JH; Morisset J; Johannson KA; Fell CD; Kolb M; Manganas H; Cox G; Gershon AS; Halayko AJ; Hambly N; Khalil N; Shapera S; To T; Wilcox PG; Guler S; Ryerson CJ
Chest; 2019 Nov; 156(5):887-895. PubMed ID: 31051170
[TBL] [Abstract][Full Text] [Related]
17. Survival differences in rheumatoid arthritis interstitial lung disease and idiopathic pulmonary fibrosis may be explained by delays in presentation: results from multivariate analysis in a monocentric UK study.
Dubey S; Woodhead F
Rheumatol Int; 2024 Jan; 44(1):99-105. PubMed ID: 38085367
[TBL] [Abstract][Full Text] [Related]
18. Tobacco smoking is associated with combined pulmonary fibrosis and emphysema and worse outcomes in interstitial lung disease.
Douglas D; Keating L; Strykowski R; Lee CT; Garcia N; Selvan K; Kaushik N; Bauer Ventura I; Jablonski R; Vij R; Chung JH; Bellam S; Strek ME; Adegunsoye A
Am J Physiol Lung Cell Mol Physiol; 2023 Aug; 325(2):L233-L243. PubMed ID: 37366539
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and prognosis of unclassifiable interstitial lung disease.
Ryerson CJ; Urbania TH; Richeldi L; Mooney JJ; Lee JS; Jones KD; Elicker BM; Koth LL; King TE; Wolters PJ; Collard HR
Eur Respir J; 2013 Sep; 42(3):750-7. PubMed ID: 23222877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
